QLQiong Li

Qiong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiong Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Daoxiang Zhang

    School of Basic Medical Sciences Anhui Medical University Hefei China

    2 shared publications
  • Dongsheng Hou

    Department of Pathology Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong China

    2 shared publications
  • Juling Wang

    School of Life Sciences Anhui Medical University Hefei China

    2 shared publications
  • Yanchun Fang

    Department of Pathology Nantong Haimen District People's Hospital Nantong China

    2 shared publications
  • Chuifang Kong

    School of Life Sciences, Anhui Medical University, Hefei, China

    1 shared publication
  • Fubao Liu

    Department of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, China

    1 shared publication

Latest Publications

  • Open Access

    Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis

    by Juan Ran, Yanchun Fang, Shengming Ruan, Juling Wang, Songbai Liu, Yuan Mao, Dongsheng Hou, Yanping Wang, Zi Ye, Qiong Li, et al.

    Isocitrate dehydrogenase 3 alpha (IDH3A) is a key rate‐limiting enzyme in the tricarboxylic acid (TCA) cycle, traditionally associated with cellular energy metabolism. However, its role in cancer remains incompletely understood. Here, we demonstrate that IDH3A is significantly overexpressed in melanoma, primarily due to DNA copy number amplification. Metabolomic analysis revealed that IDH3A overexpression enhanced multiple biosynthetic intermediates, including G6P, F6P, DHAP, and 6‐phosphogluconate, indicating metabolic reprogramming toward anabolic processes without significantly affecting ATP or lactate production. Intriguingly, IDH3A localizes to the nucleus in melanoma cells and promotes tumorigenesis independent of its dehydrogenase activity. Nuclear IDH3A interacts with transcription factor YBX1, enriching at promoter regions of oncogenes such as c‐FOS and c‐JUN, thereby suppressing apoptosis and promoting tumor growth. Furthermore, we identify NONO as a nuclear chaperone that facilitates the nuclear localization of IDH3A through direct interaction, primarily involving NONO amino acids Q166 and S207. Disruption of NONO impairs IDH3A nuclear translocation and mitigates its tumor‐promoting function. Collectively, our findings uncover a noncanonical role of IDH3A as a nuclear regulator of transcription via YBX1, offering novel insight into metabolic enzyme reprogramming in melanoma.


  • Open Access

    Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation

    by Chuifang Kong, Yanchun Fang, Lili Shen, Zhihua Shui, Mengjie Lv, Xinyu Zhang, Hanmeng Xu, Xunxia Bao, Pengwei Cao, Wenjing Ding, et al.

    Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Recent advances in immunotherapy have shown potential for improving outcomes; however, therapeutic resistance remains a challenge. We demonstrate that HAS2 is significantly upregulated in pancreatic cancer, and is associated with poor prognosis, reduced infiltration of CD4⁺ and CD8⁺ T cells, and shorter survival. Mechanistically, HAS2 stabilizes PD-L1, a key immune checkpoint molecule, by modulating K6- and K63-linked ubiquitination, enhancing PD-L1 stability and suppressing immune responses. Our study further reveals that HAS2 activates the AKT signaling pathway to downregulate March4 expression, a critical E3 ubiquitin ligase that negatively regulates PD-L1 stability, thereby promoting PD-L1 stabilization. In vivo, HAS2 knockout in KPC mice reduces PD-L1 levels, increases March4 expression, enhances T cell infiltration, and delays cancer progression. Reduced collagen deposition in HAS2⁺/⁻ tumors further underscores its role in tumor microenvironment remodeling. Targeting the HAS2-March4-PD-L1 axis through HAS2 inhibition, anti-PD-L1 therapy, or March4 overexpression suppresses tumor growth and improves survival.


  • Open Access

    Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) in Mycobacterium tuberculosis by Competing with tmRNA

    by Lei He, Peng Cui, Wanliang Shi, Qiong Li, Wenhong Zhang, Min Li, Ying Zhang

    Pyrazinamide (PZA) is a key drug for tuberculosis treatment. The active form of PZA, pyrazinoic acid (POA), appears to inhibit multiple targets in M. tuberculosis. Recently, the bifunctional enzyme Rv2783 was reported as a new target of POA. However, the mechanism by which POA inhibits Rv2783 is not yet clear. Here, we report how a new A2104C substitution in Rv2783c, identified in PZA-resistant clinical isolates, conferred resistance to PZA in M. tuberculosis. Expression of the mutant allele recapitulated the PZA resistance. All catalytic activities of Rv2783, but not the mutant, were inhibited by POA. Additionally, POA competed with transfer-messenger RNA (tmRNA) for binding to Rv2783, other than the mutant. These results provide new insight into the molecular mechanism of the antitubercular activity of PZA.